NCT02781883Phase 2Recruiting

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-12Estimated

Enrollment · participants108Estimated

Source updated2025-03-07Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Acute Myeloid Leukemia (AML)

Treatments or interventions studied

BP1001 in combination with Ventoclax plus decitabineDrugAlso known as Liposomal Grb-2, L-Grb-2
BP1001 plus decitabineDrugAlso known as Liposomal Grb-2, L-Grb-2

Primary outcomes · main study measures

Read the study measures

measure: Assessment of efficacy in untreated AML subjects by bone marrow aspirate or biopsy; description: Assess whether the combination of BP1001 and Ventoclax plus decitabine provides greater efficacy (Complete Remission \[CR\], Complete Remission with incomplete hematologic recovery \[CRi\], Complete Remission with partial hematologic recovery \[CRh\], than Ventoclax + decitabine alone (by historical comparison) with untreated AML that cannot or elect not to be treated with more intensive chemotherapy; timeFrame: 180 days; measure: Assessment of efficacy in refractory/relapsed AML subjects by bone marrow aspirate or biopsy; description: Assess whether BP1001-based treatment provides greater efficacy (CR, CRi, CRh) than intensive chemotherapy (by historical comparison) in participants with refractory/relapsed AML.; timeFrame: 180 days

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history